An Open Label Evaluation of the Safety and Clinical Utility of the Active, Separated System With Enhanced Controller (SSEC) Fentanyl 40mcg for the Management of Acute Postoperative Pain in Pediatric Patients 12 to Less Than 18 Years of Age

Trial Profile

An Open Label Evaluation of the Safety and Clinical Utility of the Active, Separated System With Enhanced Controller (SSEC) Fentanyl 40mcg for the Management of Acute Postoperative Pain in Pediatric Patients 12 to Less Than 18 Years of Age

Completed
Phase of Trial: Phase III

Latest Information Update: 15 Nov 2016

At a glance

  • Drugs Fentanyl (Primary)
  • Indications Postoperative pain
  • Focus Adverse reactions
  • Sponsors The Medicines Company
  • Most Recent Events

    • 15 Sep 2016 Status changed from recruiting to completed.
    • 30 Mar 2016 Planned End Date changed from 1 Feb 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov.
    • 30 Mar 2016 Planned primary completion date changed from 1 Feb 2016 to 1 Sep 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top